Eloxx Pharmaceuticals, Inc. (ELOX) Form 8-K — Oct 21, 2026
Eloxx Pharmaceuticals expanded its board from five to six directors and appointed Geno J. Germano, a 35-year pharma veteran and former President of Pfizer's $14 billion Global Innovative Pharma business, as an independent director. Germano received an option grant for 13,587 shares at $12.50 per share, vesting monthly over two years. The company also announced the appointment of T.R.
Key figures
- Topline data
- first half of 2029
- Option shares
- 13587
- Board size after
- 6
- Board size before
- 5
- First patient dosing
- Q3 2027
- Express enrollment target
- 60
- Option exercise price usd
- 12.5
- Express treatment duration weeks
- 52
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.